The treatment of allergic rhinitis with immunotherapy: A review of 1,000 cases

M. C. Veling, R. J. Trevino

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We conducted a 10-year retrospective chart review of 1,000 immunotherapy-treated patients to evaluate the efficacy and safety of serial dilution quantitative intradermal testing in the management of allergic rhinitis. Three months after the initiation of immunotherapy, these patients had been assessed to ascertain whether or not they had experienced any overall improvement in their initial symptoms. Also included in this evaluation were determinations of each patient's use of medications as well as the incidence of adverse reactions to treatment and recurrent sinus infections. We found that 860 patients had achieved complete relief of their symptoms and required no other treatment; the remaining 140 patients experienced a partial improvement and continued to use pharmacotherapy to control breakthrough symptoms. During skin testing, only one patient experienced a systemic reaction, which responded to subcutaneous epinephrine. There were no deaths. We conclude that serial dilution quantitative intradermal testing is safe and that quantification of skin reactivity in evaluating and treating allergic rhinitis with immunotherapy is completely effective in the vast majority of patients.

Original languageEnglish (US)
Pages (from-to)542-543
Number of pages2
JournalEar, Nose and Throat Journal
Volume80
Issue number8
StatePublished - 2001

Fingerprint

Immunotherapy
Therapeutics
Skin
Allergic Rhinitis
Epinephrine
Safety
Drug Therapy
Incidence
Infection

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

The treatment of allergic rhinitis with immunotherapy : A review of 1,000 cases. / Veling, M. C.; Trevino, R. J.

In: Ear, Nose and Throat Journal, Vol. 80, No. 8, 2001, p. 542-543.

Research output: Contribution to journalArticle

@article{4f52837ae8be4eaaab2cfe9e5282bad0,
title = "The treatment of allergic rhinitis with immunotherapy: A review of 1,000 cases",
abstract = "We conducted a 10-year retrospective chart review of 1,000 immunotherapy-treated patients to evaluate the efficacy and safety of serial dilution quantitative intradermal testing in the management of allergic rhinitis. Three months after the initiation of immunotherapy, these patients had been assessed to ascertain whether or not they had experienced any overall improvement in their initial symptoms. Also included in this evaluation were determinations of each patient's use of medications as well as the incidence of adverse reactions to treatment and recurrent sinus infections. We found that 860 patients had achieved complete relief of their symptoms and required no other treatment; the remaining 140 patients experienced a partial improvement and continued to use pharmacotherapy to control breakthrough symptoms. During skin testing, only one patient experienced a systemic reaction, which responded to subcutaneous epinephrine. There were no deaths. We conclude that serial dilution quantitative intradermal testing is safe and that quantification of skin reactivity in evaluating and treating allergic rhinitis with immunotherapy is completely effective in the vast majority of patients.",
author = "Veling, {M. C.} and Trevino, {R. J.}",
year = "2001",
language = "English (US)",
volume = "80",
pages = "542--543",
journal = "Ear, Nose and Throat Journal",
issn = "0145-5613",
publisher = "Medquest Communications LLC",
number = "8",

}

TY - JOUR

T1 - The treatment of allergic rhinitis with immunotherapy

T2 - A review of 1,000 cases

AU - Veling, M. C.

AU - Trevino, R. J.

PY - 2001

Y1 - 2001

N2 - We conducted a 10-year retrospective chart review of 1,000 immunotherapy-treated patients to evaluate the efficacy and safety of serial dilution quantitative intradermal testing in the management of allergic rhinitis. Three months after the initiation of immunotherapy, these patients had been assessed to ascertain whether or not they had experienced any overall improvement in their initial symptoms. Also included in this evaluation were determinations of each patient's use of medications as well as the incidence of adverse reactions to treatment and recurrent sinus infections. We found that 860 patients had achieved complete relief of their symptoms and required no other treatment; the remaining 140 patients experienced a partial improvement and continued to use pharmacotherapy to control breakthrough symptoms. During skin testing, only one patient experienced a systemic reaction, which responded to subcutaneous epinephrine. There were no deaths. We conclude that serial dilution quantitative intradermal testing is safe and that quantification of skin reactivity in evaluating and treating allergic rhinitis with immunotherapy is completely effective in the vast majority of patients.

AB - We conducted a 10-year retrospective chart review of 1,000 immunotherapy-treated patients to evaluate the efficacy and safety of serial dilution quantitative intradermal testing in the management of allergic rhinitis. Three months after the initiation of immunotherapy, these patients had been assessed to ascertain whether or not they had experienced any overall improvement in their initial symptoms. Also included in this evaluation were determinations of each patient's use of medications as well as the incidence of adverse reactions to treatment and recurrent sinus infections. We found that 860 patients had achieved complete relief of their symptoms and required no other treatment; the remaining 140 patients experienced a partial improvement and continued to use pharmacotherapy to control breakthrough symptoms. During skin testing, only one patient experienced a systemic reaction, which responded to subcutaneous epinephrine. There were no deaths. We conclude that serial dilution quantitative intradermal testing is safe and that quantification of skin reactivity in evaluating and treating allergic rhinitis with immunotherapy is completely effective in the vast majority of patients.

UR - http://www.scopus.com/inward/record.url?scp=0034892218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034892218&partnerID=8YFLogxK

M3 - Article

C2 - 11523472

AN - SCOPUS:0034892218

VL - 80

SP - 542

EP - 543

JO - Ear, Nose and Throat Journal

JF - Ear, Nose and Throat Journal

SN - 0145-5613

IS - 8

ER -